CAT
Caterpillar Inc.
CAT has lower modeled downside risk, despite its lower overall score.
MYRG
MYR Group Inc.
MYRG has the edge over CAT overall, supported by stronger valuation and stronger modeled upside.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
MYRG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
MYRG's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
MYRG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $214 | -23% |
| Forward | 19x | $278 | — |
| Current | 23x | $278 | — |
| Fair | 24x | $300 | +7.6% |
| Expensive | 42x | $513 | +84% |
Historical ranges are pointers, not guarantees.
MYRG has the edge over CAT in the historical PE scenario, which offers more potential upside but is not a forecast.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
MYRG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for MYRG, with profitability improving. However, they disagree widely on these estimates.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT earned $25.48 per share over the past year, up 31% from the year before.
MYRG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $14.56 | +18% |
| Q3 2026 | $12.31 | +100% |
| Q2 2026 | $10.54 | +121% |
| Q1 2026 | $9.07 | +320% |
| Q4 2025 | $7.53 | +311% |
| Q3 2025 | $6.17 | +172% |
| Q2 2025 | $4.77 | +64% |
| Q1 2025 | $2.16 | -58% |
| Q4 2024 | $1.83 | -66% |
MYRG has the edge over CAT on earnings, with more consistent year-over-year improvement.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over MYRG on profitability, with a higher operating margin.
MYRG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +32% |
| Q2 2026 | $1.1B | +20% |
| Q1 2026 | $1B | +20% |
| Q4 2025 | $973.5M | +17% |
| Q3 2025 | $950.4M | +7% |
| Q2 2025 | $900.3M | +8.6% |
| Q1 2025 | $833.6M | +2.2% |
| Q4 2024 | $829.8M | -17% |
MYRG's revenue has grown year over year for seven quarters in a row: $1.3B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | +1.9 points |
| Q2 2026 | 6.3% | +1.9 points |
| Q1 2026 | 6.5% | +2.4 points |
| Q4 2025 | 4.8% | +1.2 points |
| Q3 2025 | 4.9% | +2.6 points |
| Q2 2025 | 4.4% | +6.9 points |
| Q1 2025 | 4.1% | +1.1 points |
| Q4 2024 | 3.6% | -0.1 points |
MYRG's operating margin was 6.8% last quarter, up 1.9 points from the same quarter a year ago, near the top of its range since 2019.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
MYRG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.2M | -86% |
| Q2 2026 | -$25.6M | -320% |
| Q1 2026 | $68.6M | -2.3% |
| Q4 2025 | $84.9M | +863% |
| Q3 2025 | $65.4M | +264% |
| Q2 2025 | $11.6M | +365% |
| Q1 2025 | $70.2M | +$88.3M |
| Q4 2024 | $8.8M | -59% |
MYRG generated $137M in free cash flow over the past year, down 12% from the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over MYRG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
MYRG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -10K shares |
| 1 year | +0.6% | +90K shares |
| 3 years | -6.6% | -1.1M shares |
| 5 years | -8.4% | -1.4M shares |
| Available history | -5.9% | -978K shares |
MYRG has 16M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.3M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $75M |
| Q4 2024 | — |
MYRG has spent almost nothing on buybacks in the past year.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over MYRG on leverage, with a lower net debt burden relative to earnings.
MYRG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.6x | Very low |
MYRG's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
MYRG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 27.3 | Neutral |
MYRG's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
MYRG PE vs Industrials Sector
| Metric | MYRG | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 24x | 6% below |
| PE % | 44 | 58 | 14 pts below |
MYRG has the edge over CAT on valuation relative to its sector.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
MYRG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $283.5 | 1.8% below |
| 20 week MA | $317.9 | 12% below |
| 50 week MA | $319.0 | 13% below |
| 100 week MA | $242.7 | 15% above |
| 200 week MA | $188.7 | 48% above |
MYRG has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 48% above its 200-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.
MYRG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.1 | $60.4 | +88% |
| 2021 | $60.4 | $106.9 | +77% |
| 2022 | $106.9 | $90.3 | -16% |
| 2023 | $90.3 | $144.6 | +60% |
| 2024 | $144.6 | $150.1 | +3.8% |
| 2025 | $150.1 | $225.1 | +50% |
| 2026 YTD | $225.1 | $278.4 | +24% |
MYRG has the edge over CAT on returns for 2026, with the stronger performance.